Leading brain tumor experts meet for ReMission Summit 2023
Fifth annual ReMission Summit brought together top brain tumor researchers and clinicians to advance new treatments.
Fifth annual ReMission Summit brought together top brain tumor researchers and clinicians to advance new treatments.
Scientists at The Wertheim UF Scripps Institute report that a common amino acid can deliver a “slow-down” signal to the brain, likely influencing major depression, anxiety and other mood disorders in some people.
Catch up on some of the latest neuroscience and neuromedicine research news around the MBI and beyond.
Dr. Michalina Janiszewska, Ph.D., a cancer biologist at The Herbert Wertheim UF Scripps Institute, offers insight into glioblastoma mechanisms.
To celebrate Brain Awareness Week, UF neuroscience students brought interactive demonstrations to K-12 students.
SKYCLARYS was tested and approved by the FDA to treat Friedrich’s ataxia.
Tara Hearns to serve as chief operating officer, overseeing day-to-day operations at the Norman Fixel Institute.
Jaffee is the founding director of UF’s Brain Injury, Rehabilitation and Neuroresilience Center and is board certified in neurology, psychiatry, sleep medicine and brain injury medicine with additional certifications in behavioral neurology and neuropsychiatry.
Pilot study led by UF neurologists showed that biphasic DBS was safe, well tolerated and may provide faster benefit for patients with primary dystonia.
Supporting translational and basic research on facial pain related to trigeminal neuralgia and other nerve-related causes of facial pain inclusive of headaches and multiple sclerosis.